Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol

Endocrinology. 1996 May;137(5):1735-44. doi: 10.1210/endo.137.5.8612509.

Abstract

Modulation of steroid receptor-dependent transcription by extra- cellular ligands represents a novel mechanism of steroid receptor regulation. We have assessed the effects of epidermal growth factor (EGF), transforming growth factor-alpha (TGF alpha), and insulin-like growth factor I (IGF-I) on transcription from consensus estrogen response elements (ERE) in estrogen receptor (ER)-positive BG-1 human ovarian adenocarcinoma calls. EGF, TGF alpha, IGF-I, and estradiol (E2) enhanced transcription in a dose-dependent manner using either a strong or a minimal promoter, and ICI 164,384, a specific ER antagonist, inhibited these responses. Combinations of E2 with TGF alpha or IGF-I induced synergistic activation of transcription from an ERE, whereas as additive response was observed with combinations of IGF-I and TGF alpha of EGF. Tetradecanoyl 12-phorbol 13-acetate (TPA), a protein kinase C (PKC) activator, stimulated ERE-mediated transcription, and this effect was inhibited by ICI 164,384. Bisindolylmaleimide, a relatively specific inhibitor of PKC, completely antagonized TPA-induced transcription, but did not affect the response to TGF alpha, IGF-I, or E2. The combination of TPA with E2 in transcriptional synergism was inhibited by ICI 164,384; conversely, the combination of TPA with either TGF alpha of IGF-I elicited a response only equal to the maximal TPA response. Thus, peptide growth factors elicit ER-dependent transcription independently of PFC; however, there may be a common mechanistic component, as saturation of response was observed. Finally, activation of ERE-dependent transcription in Chinese hamster ovary cells by IGF-I was observed in the presence of a mutant receptor that lacks estrogen-binding activity. The effect of both IGF-I and E2 were dependent on the ability of the ER to bind to DNA. IGF-I elicited only weak transcriptional activation in the presence of a deletion mutant that lacked the entire A/B domain; however, synergism between IGF-I and E2 was observed with this mutant. Therefore, ligand-independent activation of ER-dependent transcription by IGF-I is predominantly mediated through activation function I by a mechanism distinct from that of E2.

MeSH terms

  • 8-Bromo Cyclic Adenosine Monophosphate / pharmacology
  • Animals
  • Base Sequence
  • Binding Sites
  • CHO Cells
  • Cell Division / drug effects
  • Cricetinae
  • Epidermal Growth Factor / pharmacology*
  • Estradiol / pharmacology*
  • Humans
  • Insulin-Like Growth Factor I / pharmacology*
  • Molecular Sequence Data
  • Protein Kinase C / metabolism*
  • Receptors, Estrogen / metabolism*
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transcription, Genetic
  • Transforming Growth Factor alpha / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Receptors, Estrogen
  • Transforming Growth Factor alpha
  • 8-Bromo Cyclic Adenosine Monophosphate
  • Estradiol
  • Epidermal Growth Factor
  • Insulin-Like Growth Factor I
  • Protein Kinase C
  • Tetradecanoylphorbol Acetate